From WikiProjectMed
Jump to navigation Jump to search
Trade namesQulipta
Other namesAGN-241689, MK-8031
  • (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
Clinical data
Drug classGepant[1]
Main usesPrevention of migraines[2]
Side effectsNausea, constipation, tiredness[2]
Routes of
By mouth
External links
License data
Legal status
Chemical and physical data
Molar mass603.525 g·mol−1
3D model (JSmol)
  • C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
  • InChI=1S/C29H23F6N5O3/c1-13-16(22-18(30)4-5-19(31)23(22)32)8-20(26(42)40(13)12-29(33,34)35)38-25(41)15-7-14-9-28(10-21(14)37-11-15)17-3-2-6-36-24(17)39-27(28)43/h2-7,11,13,16,20H,8-10,12H2,1H3,(H,38,41)(H,36,39,43)/t13-,16-,20+,28+/m1/s1

Atogepant, sold under the brand name Qulipta, is a medication used to prevent migraines.[2] It is taken by mouth once per day.[2] Its use dose not appear to result in medication overuse headaches.[3]

Commons side effects include nausea, constipation, and tiredness.[2] Use in pregnancy may harm the baby.[2] It should not be taken by people with significant liver problems.[2] It is a calcitonin gene-related peptide receptor (CGRPR) antagonist, specifically a gepant.[2][1]

Atogepant was approved for medical use in the United States in 2021.[2] As of 2022 it is not approved in either Europe or the United Kingdom.[4] In the United States it costs about 1,000 USD per month.[5]

Medical uses

Atogepant is used to preventive treatment of episodic migraine in adults.[2]


It is taken at a dose of 10 to 60 mg once per day.[2]


A study found it reduced the number of migraine days over twelve weeks.[6]


  1. 1.0 1.1 Tepper, Deborah (May 2020). "Gepants". Headache: The Journal of Head and Face Pain. 60 (5): 1037–1039. doi:10.1111/head.13791.
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 "Qulipta- atogepant tablet". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
  3. "Atogepant Monograph for Professionals". Archived from the original on 24 February 2024. Retrieved 27 October 2022.
  4. "Atogepant". SPS - Specialist Pharmacy Service. 5 October 2017. Archived from the original on 7 December 2021. Retrieved 27 October 2022.
  5. "Qulipta". Archived from the original on 27 October 2022. Retrieved 27 October 2022.
  6. Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. (August 2021). "Atogepant for the Preventive Treatment of Migraine". The New England Journal of Medicine. 385 (8): 695–706. doi:10.1056/NEJMoa2035908. PMID 34407343.

External links

External sites: